Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Rachel Clark Sisodia, M.D.

Co-Author

This page shows the publications co-authored by Rachel Sisodia and Marcela del Carmen.
Connection Strength

4.697
  1. Effect of Educational Intervention on Cervical Cancer Prevention and Screening in Hispanic Women. J Community Health. 2015 Dec; 40(6):1178-84.
    View in: PubMed
    Score: 0.330
  2. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer. Am J Obstet Gynecol. 2015 May; 212(5):600.e1-8.
    View in: PubMed
    Score: 0.308
  3. Primary care physician's (PCP) perceived value of patient-reported outcomes (PROs) in clinical practice: a mixed methods study. BMJ Qual Saf. 2021 May 20.
    View in: PubMed
    Score: 0.241
  4. Implementing ERAS: how we achieved success within an anesthesia department. BMC Anesthesiol. 2021 02 05; 21(1):36.
    View in: PubMed
    Score: 0.236
  5. Patient reported outcome measures among patients with vulvar cancer at various stages of treatment, recurrence, and survivorship. Gynecol Oncol. 2021 01; 160(1):252-259.
    View in: PubMed
    Score: 0.232
  6. Factors associated with referral and completion of genetic counseling in women with epithelial ovarian cancer. Int J Gynecol Cancer. 2020 09; 30(9):1397-1403.
    View in: PubMed
    Score: 0.225
  7. Factors Associated With Increased Collection of Patient-Reported Outcomes Within a Large Health Care System. JAMA Netw Open. 2020 04 01; 3(4):e202764.
    View in: PubMed
    Score: 0.223
  8. Gynecologic oncology care in the world of accountable care organizations. Gynecol Oncol Rep. 2019 Nov; 30:100507.
    View in: PubMed
    Score: 0.216
  9. Intraoperative Radiation Therapy in the Management of Gynecologic Malignancies. Am J Clin Oncol. 2016 08; 39(4):329-34.
    View in: PubMed
    Score: 0.173
  10. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer. 2016 Nov 15; 122(21):3297-3306.
    View in: PubMed
    Score: 0.172
  11. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis. Gynecol Oncol. 2016 Jul; 142(1):38-43.
    View in: PubMed
    Score: 0.170
  12. Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis. Int J Gynecol Cancer. 2016 May; 26(4):697-704.
    View in: PubMed
    Score: 0.170
  13. Mucinous Adenocarcinoma of the Endometrium Compared With Endometrioid Endometrial Cancer: A SEER Analysis. Am J Clin Oncol. 2016 Feb; 39(1):43-8.
    View in: PubMed
    Score: 0.167
  14. Trends in Treatment of Uterine Serous Cancer in the Medicare Population. Int J Gynecol Cancer. 2015 Jul; 25(6):1023-30.
    View in: PubMed
    Score: 0.160
  15. Incidence and effects on mortality of venous thromboembolism in elderly women with endometrial cancer. Obstet Gynecol. 2015 Jun; 125(6):1362-1370.
    View in: PubMed
    Score: 0.159
  16. Trends in the treatment of uterine leiomyosarcoma in the Medicare population. Int J Gynecol Cancer. 2015 Mar; 25(3):453-8.
    View in: PubMed
    Score: 0.156
  17. Transitional cell carcinoma of the ovary: a case-control study. Gynecol Oncol. 2014 Mar; 132(3):649-53.
    View in: PubMed
    Score: 0.145
  18. Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis. Gynecol Oncol. 2013 Nov; 131(2):404-9.
    View in: PubMed
    Score: 0.141
  19. Racial disparities in cervical cancer survival over time. Cancer. 2013 Oct 15; 119(20):3644-52.
    View in: PubMed
    Score: 0.140
  20. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol. 2013 Oct; 131(1):46-51.
    View in: PubMed
    Score: 0.140
  21. Racial disparities and changes in clinical characteristics and survival for vulvar cancer over time. Am J Obstet Gynecol. 2013 Nov; 209(5):468.e1-468.e10.
    View in: PubMed
    Score: 0.140
  22. Patient, treatment and discharge factors associated with hospital readmission within 30 days after surgical cytoreduction for epithelial ovarian carcinoma. Gynecol Oncol. 2013 Sep; 130(3):407-10.
    View in: PubMed
    Score: 0.139
  23. Predictive validity of American College of Surgeons: National Surgical Quality Improvement Project risk calculator in patients with ovarian cancer undergoing interval debulking surgery. Int J Gynecol Cancer. 2021 10; 31(10):1356-1362.
    View in: PubMed
    Score: 0.062
  24. Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer. Int J Gynecol Cancer. 2021 10; 31(10):1341-1347.
    View in: PubMed
    Score: 0.061
  25. Lymph node assessment at the time of hysterectomy has limited clinical utility for patients with pre-cancerous endometrial lesions. Gynecol Oncol. 2021 Sep; 162(3):613-618.
    View in: PubMed
    Score: 0.061
  26. Enhanced Recovery After Surgery Patients are Prescribed Fewer Opioids at Discharge: A Propensity-Score Matched Analysis. Ann Surg. 2021 Jul 02.
    View in: PubMed
    Score: 0.061
  27. The Surgeon's Perceived Value of Patient-reported Outcome Measures (PROMs): An Exploratory Qualitative Study of 5 Different Surgical Subspecialties. Ann Surg. 2020 Jul 09.
    View in: PubMed
    Score: 0.057
  28. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer. Int J Gynecol Cancer. 2020 07; 30(7):1052-1057.
    View in: PubMed
    Score: 0.056
  29. Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy. Obstet Gynecol. 2017 05; 129(5):861-869.
    View in: PubMed
    Score: 0.045
  30. Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. Gynecol Oncol. 2015 Jun; 137(3):401-5.
    View in: PubMed
    Score: 0.039
  31. Surgical Apgar Score and prediction of morbidity in women undergoing hysterectomy for malignancy. Gynecol Oncol. 2015 Mar; 136(3):516-20.
    View in: PubMed
    Score: 0.038
  32. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol. 2014 May; 133(2):216-20.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.